Marvel Biosciences Signs Letter of Intent with Novatech for MB-204 Trial

Marvel Biosciences Corp. announced it has signed a Letter of Intent with Novatech for the Phase 1 trial of its drug candidate MB-204, intended for autism spectrum disorder. The company also provided a general corporate update.